Daré Bioscience, Inc.
DARENASDAQHealthcare● Active
$1.85
$-0.03(-1.60%)
Market Cap$17615082
P/E Ratio—
52W High$9.19
52W Low$1.27
Daré Bioscience, Inc. (DARE) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
DARE · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.20
Est. -$0.33 · +39.4%
Revenue
$0.00B
Est. $0.00B · +464.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 8-Quarter EPS Beat Streak
DARE reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.33 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 14, 2026 | -$0.33 | -$0.20 | +39.4% | $0.00B | $0.00B | +464.6% |
| ▲ Q1 FY2026 | Mar 26, 2026 | -$0.24 | -$0.02 | +91.7% | $0.00B | $0.00B | +36.2% |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$0.33 | -$0.28 | +15.2% | $0.00B | $0.00B | -99.7% |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.55 | -$0.45 | +18.2% | $-0.00B | $0.00B | -114.4% |
| ▲ Q2 FY2025 | May 13, 2025 | -$0.63 | -$0.50 | +20.6% | $0.00B | $0.00B | -95.8% |
| ▲ Q1 FY2025 | Mar 31, 2025 | -$0.66 | -$0.64 | +3.0% | $-0.00B | $0.00B | -106.4% |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$0.60 | -$0.55 | +8.3% | $0.00B | $0.00B | -95.8% |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.33
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Beat
EPS Actual
-$0.20
EPS Est.
-$0.33
EPS Surpr.
+39.4%
Revenue
$0.00B
Q1 FY2026
Mar 26, 2026Beat
EPS Actual
-$0.02
EPS Est.
-$0.24
EPS Surpr.
+91.7%
Revenue
$0.00B
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$0.28
EPS Est.
-$0.33
EPS Surpr.
+15.2%
Revenue
$0.00B
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.45
EPS Est.
-$0.55
EPS Surpr.
+18.2%
Revenue
$-0.00B
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$0.50
EPS Est.
-$0.63
EPS Surpr.
+20.6%
Revenue
$0.00B
Q1 FY2025
Mar 31, 2025Beat
EPS Actual
-$0.64
EPS Est.
-$0.66
EPS Surpr.
+3.0%
Revenue
$-0.00B
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$0.55
EPS Est.
-$0.60
EPS Surpr.
+8.3%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.00 | $0.00 | $0.00 | 1 |
| Q3 FY2028 | $0.00 | $0.00 | $0.00 | 1 |
| Q2 FY2028 | $0.00 | $0.00 | $0.00 | 1 |
| Q1 FY2028 | $0.00 | $0.00 | $0.00 | 1 |
| Q4 FY2027 | $-0.12 | $-0.12 | $-0.12 | 1 |
| Q3 FY2027 | $-0.12 | $-0.12 | $-0.12 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +39.4% | $2.84 | $2.86 | +0.70% |
| ▲ Q1 FY2026 | Mar 26, 2026 | +91.7% | $1.40 | $1.51 | +7.86% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +15.2% | $1.98 | $1.89 | -4.55% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +18.2% | $2.11 | $2.07 | -1.90% |
| ▲ Q2 FY2025 | May 13, 2025 | +20.6% | $2.88 | $2.89 | +0.35% |
| ▲ Q1 FY2025 | Mar 31, 2025 | +3.0% | $2.88 | $2.89 | +0.35% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +8.3% | $3.84 | $3.57 | -7.03% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +366.7% | $3.39 | $3.50 | +3.24% |
Q2 FY2026+0.70%
Report Date
May 14, 2026
EPS Beat/Miss
+39.4%
Price Before
$2.84
Price After
$2.86
Q1 FY2026+7.86%
Report Date
Mar 26, 2026
EPS Beat/Miss
+91.7%
Price Before
$1.40
Price After
$1.51
Q4 FY2025-4.55%
Report Date
Nov 13, 2025
EPS Beat/Miss
+15.2%
Price Before
$1.98
Price After
$1.89
Q3 FY2025-1.90%
Report Date
Aug 14, 2025
EPS Beat/Miss
+18.2%
Price Before
$2.11
Price After
$2.07
Q2 FY2025+0.35%
Report Date
May 13, 2025
EPS Beat/Miss
+20.6%
Price Before
$2.88
Price After
$2.89
Q1 FY2025+0.35%
Report Date
Mar 31, 2025
EPS Beat/Miss
+3.0%
Price Before
$2.88
Price After
$2.89
Q4 FY2024-7.03%
Report Date
Nov 14, 2024
EPS Beat/Miss
+8.3%
Price Before
$3.84
Price After
$3.57
Q3 FY2024+3.24%
Report Date
Aug 12, 2024
EPS Beat/Miss
+366.7%
Price Before
$3.39
Price After
$3.50
Avg Beat Reaction-0.12%
Beat Rate8 / 8 quarters
Largest Move+7.86% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: DARE ends December
Daré Bioscience, Inc. (DARE) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.20 — beating the analyst consensus of $-0.33 by +39.4%. DARE has beaten EPS estimates for 8 consecutive quarters. The next DARE earnings date is expected around September 1, 2026.
Each quarter, investors track DARE earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. DARE revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
DARE's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
DARE earnings · 5 questionsDaré Bioscience, Inc.'s next earnings report is expected around September 1, 2026. DARE typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; DARE historically reports after market close (AMC).
DARE earnings datewhen is DARE earningsDARE next earnings datewhen does DARE report earningsDARE earnings calendar
▸ Source: FMP · Daré Bioscience, Inc. SEC filings · US GAAP · Daré Bioscience, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026